Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
45.47
-0.29 (-0.63%)
Nov 21, 2024, 1:21 PM EST - Market open
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $290.08M in the quarter ending September 30, 2024, with 34.28% growth. This brings the company's revenue in the last twelve months to $947.36M, up 21.35% year-over-year. In the year 2023, Halozyme Therapeutics had annual revenue of $829.25M with 25.62% growth.
Revenue (ttm)
$947.36M
Revenue Growth
+21.35%
P/S Ratio
6.16
Revenue / Employee
$2,539,826
Employees
373
Market Cap
5.79B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
Dec 31, 2019 | 195.99M | 44.13M | 29.06% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
R1 RCM | 2.46B |
RadNet | 1.77B |
Lantheus Holdings | 1.50B |
Waystar Holding | 906.14M |
Ionis Pharmaceuticals | 803.07M |
Inspire Medical Systems | 755.59M |
Corcept Therapeutics | 628.56M |
Blueprint Medicines | 434.42M |
HALO News
- 3 days ago - Halozyme says €2 billion takeover of Evotech would create leader in drug discovery - Market Watch
- 3 days ago - Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec - PRNewsWire
- 6 days ago - Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - Benzinga
- 6 days ago - Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction - PRNewsWire
- 6 days ago - Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports - Reuters
- 16 days ago - Halozyme: Looking For More Growth Following Record Q3 Earnings - Seeking Alpha
- 20 days ago - Halozyme Announces Record Earnings, Guidance - FXEmpire
- 20 days ago - Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript - Seeking Alpha